Paulson Cut Stakes in Money-Losing Pharma Stocks Last Quarter
Paulson Cut Stakes in Money-Losing Pharma Stocks Last Quarter
(Bloomberg) -- Hedge fund manager John Paulson reduced his stakes in several health-care stocks that have been dumped by investors this year.
In the third quarter, Paulson & Co. cut its position in generic drugmaker Teva Pharmaceutical Industries Ltd. by more than 60 percent, according to a regulatory filing Tuesday. Teva’s American depositary receipts have declined 68 percent in 2017. He reduced the number of shares he holds in Allergan Plc by almost 20 percent. Allergan, a maker of specialty pharmaceuticals, fell 18 percent this year.
In July, the firm said it was closing a two-year-old long-short equity fund to shift strategies after a steep drop in assets. The fund focused on health-care and pharmaceutical bets.
Paulson in the third quarter also sold 1.2 million shares of Mylan NV; 328,200 shares of Shire Plc; 974,400 shares of Valeant Pharmaceuticals International Inc. and 264,700 shares of Mallinckrodt Plc, according to the filing.
Paulson & Co. shot to fame betting on the collapse of the U.S. housing market. At his peak in 2011 Paulson managed $38 billion, half of it from outside investors. In June, Bloomberg News reported the firm managed $10 billion, including about $2 billion of client money.
To contact the reporter on this story: Charles Stein in Boston at cstein4@bloomberg.net.
To contact the editors responsible for this story: Margaret Collins at mcollins45@bloomberg.net, Alan Mirabella, Josh Friedman
©2017 Bloomberg L.P.